Evaluation of immune responses to Brucella vaccines in mouse models: A systematic review

Darbandi, Atieh; Alamdary, Shabnam Zeighamy; Koupaei, Maryam; Ghanavati, Roya; Heidary, Mohsen; Talebi, Malihe

doi:10.3389/fvets.2022.903890

Cited by 6 publications

(6 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the lack of a safe and effective Brucella vaccine for humans, animal vaccinations are essential not only to safeguard animal health, but also to prevent the spreading of diseases transmitted from animals to humans. Several drawbacks of these vaccines have been reported by Darbandi et al [ 157 ]. Among these are: (i) they remain virulent in humans; (ii) they cause abortion in pregnant animals; (iii) it can be difficult to differentiate between infected and vaccinated animals due to the persistent serological response they induce; (iv) they are relatively unstable.…”

Section: Brucella Vaccine Developmentmentioning

confidence: 99%

See 1 more Smart Citation

The Development of Diagnostic and Vaccine Strategies for Early Detection and Control of Human Brucellosis, Particularly in Endemic Areas

et al. 2023

View full text Add to dashboard Cite

Brucellosis is considered one of the most serious zoonotic diseases worldwide. This disease affects both human and animal health, in addition to being one of the most widespread zoonotic illnesses in the Middle East and Northern Africa. Human brucellosis generally presents in a diverse and non-specific manner, making laboratory confirmation of the diagnosis critical to the patient’s recovery. A coordinated strategy for diagnosing and controlling brucellosis throughout the Middle East is required, as this disease cannot be known to occur without reliable microbiological, molecular, and epidemiological evidence. Consequently, the current review focuses on the current and emerging microbiological diagnostic tools for the early detection and control of human brucellosis. Laboratory assays such as culturing, serology, and molecular analysis can frequently be used to diagnose brucellosis. Although serological markers and nucleic acid amplification techniques are extremely sensitive, and extensive experience has been gained with these techniques in the laboratory diagnosis of brucellosis, a culture is still considered to be the “gold standard” due to the importance of this aspect of public health and clinical care. In endemic regions, however, serological tests remain the primary method of diagnosis due to their low cost, user-friendliness, and strong ability to provide a negative prediction, so they are commonly used. A nucleic acid amplification assay, which is highly sensitive, specific, and safe, is capable of enabling rapid disease diagnosis. Patients who have reportedly fully healed may continue to have positive molecular test results for a long time. Therefore, cultures and serological methods will continue to be the main tools for diagnosing and following up on human brucellosis for as long as no commercial tests or studies demonstrate adequate interlaboratory reproducibility. As there is no approved vaccine that prevents human brucellosis, vaccination-based control of animal brucellosis has become an important part of the management of human brucellosis. Over the past few decades, several studies have been conducted to develop Brucella vaccines, but the problem of controlling brucellosis in both humans and animals remains challenging. Therefore, this review also aims to present an updated overview of the different types of brucellosis vaccines that are currently available.

show abstract

Section: Brucella Vaccine Developmentmentioning

confidence: 99%

“…DNA vaccines are suitable for diseases that require cellular immunity. Human studies have shown that these vaccines induce weaker immune responses than mice; therefore, they need to be optimized [ 157 ]. Optimization, however, increases pro-inflammatory reactions [ 178 ].…”

Section: Brucella Vaccine Developmentmentioning

confidence: 99%

The Development of Diagnostic and Vaccine Strategies for Early Detection and Control of Human Brucellosis, Particularly in Endemic Areas

et al. 2023

View full text Add to dashboard Cite

show abstract

“…To ascertain its effectiveness for vaccination, the IP route was selected since it better mimics disease outcome resulting in a systemic disease [ 6 , 7 ]. Moreover, IP vaccination has proven effective in experimental models in conferring protection and significant brucellae clearance [ 41 ]. A limitation with conventional Brucella vaccines lies in their incomplete efficacy, providing only about 70% efficacy against wt Brucella abortion challenges [ 11 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

Parenteral Vaccination with a Live Brucella melitensis Mutant Protects against Wild-Type B. melitensis 16M Challenge

Yang,

Goodwin,

Bhagyaraj

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Susceptibility to brucellosis remains prevalent, even in herds vaccinated with conventional vaccines. Efforts are underway to develop an improved brucellosis vaccine, and possibly a universal vaccine, given that Brucella species are highly homologous. To this end, two B. melitensis mutants were developed, znBM-lacZ (znBMZ) and znBM-mCherry (znBM-mC), and were tested for their ability to confer systemic immunity against virulent B. melitensis challenge. To assess the extent of their attenuation, bone-marrow-derived macrophages and human TF-1 myeloid cells were infected with both mutants, and the inability to replicate within these cells was noted. Mice infected with varying doses of znBM-mC cleared the brucellae within 6–10 weeks. To test for efficacy against systemic disease, groups of mice were vaccinated once by the intraperitoneal route with either znBMZ or B. abortus S19 vaccine. Relative to the PBS-dosed mice, znBMZ vaccination greatly reduced splenic brucellae colonization by ~25,000-fold compared to 700-fold for S19-vaccinated mice. Not surprisingly, both znBMZ and S19 strains induced IFN-γ+ CD4+ T cells, yet only znBMZ induced IFN-γ+ CD8+ T cells. While both strains induced CD4+ effector memory T cells (Tems), only znBMZ induced CD8+ Tems. Thus, these results show that the described znBM mutants are safe, able to elicit CD4+ and CD8+ T cell immunity without a boost, and highly effective, rendering them promising vaccine candidates for livestock.

show abstract

“…The lack of effective treatments for animal brucellosis and the high cost of treating infected humans ( 5 , 12 ) emphasize the necessity for robust disease prevention. Current vaccines such as S19, RB51, and Rev1 exhibit around 70% efficacy against animal brucellosis ( 13 – 15 ), underscoring the need for further research on vaccine-mediated immunity.…”

Section: Introductionmentioning

confidence: 99%

Contrasting roles for IgM and B-cell MHCII expression in Brucella abortus S19 vaccine-mediated efficacy against B. melitensis infection

Abushahba,

Dadelahi,

Ponzilacqua-Silva

et al. 2024

mSphere

View full text Add to dashboard Cite

Brucella is a neglected zoonotic pathogen with a worldwide distribution. Our study delves into B-cell effector functions in live vaccine-mediated immunity against brucellosis. Notably, we found antibody production, particularly secretory IgM, confers protection against virulent Brucella melitensis in vaccinated mice, which was associated with complement activation. By contrast, B-cell MHCII expression negatively impacted vaccine efficacy. In addition, B-cell depletion after vaccination, but before the B. melitensis challenge, enhanced protection against infection, suggesting a detrimental B-cell role during the challenge phase. Interestingly, deficiency of T follicular helper cells, which are crucial for aiding germinal center B cells, dampened vaccine efficacy at later stages of challenge independent of antibody production. This study underscores contrasting and phase-dependent roles of B-cell effector functions in vaccine-mediated immunity against Brucella .

show abstract

Evaluation of immune responses to Brucella vaccines in mouse models: A systematic review

Cited by 6 publications

References 53 publications

The Development of Diagnostic and Vaccine Strategies for Early Detection and Control of Human Brucellosis, Particularly in Endemic Areas

The Development of Diagnostic and Vaccine Strategies for Early Detection and Control of Human Brucellosis, Particularly in Endemic Areas

Parenteral Vaccination with a Live Brucella melitensis Mutant Protects against Wild-Type B. melitensis 16M Challenge

Contrasting roles for IgM and B-cell MHCII expression in Brucella abortus S19 vaccine-mediated efficacy against B. melitensis infection

Contact Info

Product

Resources

About